PURPOSE: The aim of this work was to demonstrate an immunostimulatory and adjuvant effect of new apyrogenic lipophilic derivatives of norAbuMDP and norAbuGMDP formulated in nanoliposomes. METHODS: Nanoliposomes and metallochelating nanoliposomes were prepared by lipid film hydration and extrusion methods. The structure of the liposomal formulation was studied by electron microscopy, AF microscopy, and dynamic light scattering. Sublethal and lethal γ-irradiation mice models were used to demonstrate stimulation of innate immune system. Recombinant Hsp90 antigen (Candida albicans) bound onto metallochelating nanoliposomes was used for immunisation of mice to demonstrate adjuvant activities of tested compounds. RESULTS: Safety and stimulation of innate and adaptive immunity were demonstrated on rabbits and mice. The liposomal formulation of norAbuMDP/GMDP was apyrogenic in rabbit test and lacking any side effect in vivo. Recovery of bone marrow after sublethal γ-irradiation as well as increased survival of mice after lethal irradiation was demonstrated. Enhancement of specific immune response was demonstrated for some derivatives incorporated in metallochelating nanoliposomes with recombinant Hsp90 protein antigen. CONCLUSIONS: Liposomal formulations of new lipophilic derivatives of norAbuMDP/GMDP proved themselves as promising adjuvants for recombinant vaccines as well as immunomodulators for stimulation of innate immunity and bone-marrow recovery after chemo/radio therapy of cancer.
PURPOSE: The aim of this work was to demonstrate an immunostimulatory and adjuvant effect of new apyrogenic lipophilic derivatives of norAbuMDP and norAbuGMDP formulated in nanoliposomes. METHODS: Nanoliposomes and metallochelating nanoliposomes were prepared by lipid film hydration and extrusion methods. The structure of the liposomal formulation was studied by electron microscopy, AF microscopy, and dynamic light scattering. Sublethal and lethal γ-irradiation mice models were used to demonstrate stimulation of innate immune system. Recombinant Hsp90 antigen (Candida albicans) bound onto metallochelating nanoliposomes was used for immunisation of mice to demonstrate adjuvant activities of tested compounds. RESULTS: Safety and stimulation of innate and adaptive immunity were demonstrated on rabbits and mice. The liposomal formulation of norAbuMDP/GMDP was apyrogenic in rabbit test and lacking any side effect in vivo. Recovery of bone marrow after sublethal γ-irradiation as well as increased survival of mice after lethal irradiation was demonstrated. Enhancement of specific immune response was demonstrated for some derivatives incorporated in metallochelating nanoliposomes with recombinant Hsp90 protein antigen. CONCLUSIONS: Liposomal formulations of new lipophilic derivatives of norAbuMDP/GMDP proved themselves as promising adjuvants for recombinant vaccines as well as immunomodulators for stimulation of innate immunity and bone-marrow recovery after chemo/radio therapy of cancer.
Authors: Michal Křupka; Josef Mašek; Eliška Bartheldyová; Pavlína Turánek Knötigová; Jana Plocková; Zina Korvasová; Michaela Škrabalová; Štěpán Koudelka; Pavel Kulich; Kateřina Zachová; Lýdie Czerneková; Ondřej Strouhal; Milada Horynová; Marek Šebela; Andrew D Miller; Miroslav Ledvina; Milan Raška; Jaroslav Turánek Journal: J Control Release Date: 2012-02-22 Impact factor: 9.776
Authors: Jaroslav Turánek; Miroslav Ledvina; Andrea Kasná; Antonín Vacek; Vera Hríbalova; Josef Krejcí; Andrew D Miller Journal: Vaccine Date: 2006-04-12 Impact factor: 3.641
Authors: Michael H Shaw; Thornik Reimer; Carmen Sánchez-Valdepeñas; Neil Warner; Yun-Gi Kim; Manuel Fresno; Gabriel Nuñez Journal: Nat Immunol Date: 2009-11-01 Impact factor: 25.606
Authors: Michal Krupka; Josef Masek; Lucia Barkocziova; Pavlina Turanek Knotigova; Pavel Kulich; Jana Plockova; Robert Lukac; Eliska Bartheldyova; Stepan Koudelka; Radka Chaloupkova; Marek Sebela; Daniel Zyka; Ladislav Droz; Roman Effenberg; Miroslav Ledvina; Andrew D Miller; Jaroslav Turanek; Milan Raska Journal: PLoS One Date: 2016-02-05 Impact factor: 3.240
Authors: Brenda Kischkel; Suélen A Rossi; Samuel R Santos; Joshua D Nosanchuk; Luiz R Travassos; Carlos P Taborda Journal: Front Cell Infect Microbiol Date: 2020-09-03 Impact factor: 5.293